Boston Scientific delivered an impressive start to the year with $4.66 billion in revenue, a 20.9% increase year-over-year. Net income rose to $674 million, while adjusted EPS reached $0.75. The cardiovascular segment led performance with 25.6% organic growth, and U.S. sales jumped over 30%.
Total revenue increased 20.9% year-over-year to $4.66 billion
Net income rose to $674 million, up from $495 million the prior year
Adjusted EPS reached $0.75, beating guidance
Cardiovascular segment and U.S. sales were key growth drivers
Boston Scientific expects continued revenue and earnings growth in Q2 and full-year 2025, driven by operational execution and innovation, despite potential macroeconomic and supply chain risks.
Visualization of income flow from segment revenue to net income